Breaking News Headlines Today | Ground News

See every side of every news story

biopharmadive.com image

News from biopharmadive.com

The Ground News media bias check for biopharmadive.com is Center. Scores are assigned by aggregating bias scores from Ad Fontes Media, Media Bias/Fact Check, and All Sides.

biopharmadive.com’s aggregated factuality score is High. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about biopharmadive.com

Where is biopharmadive.com located?biopharmadive.com's Website

Media Bias Ratings

Average Bias Rating:

Center

Center

byMedia Bias/Fact Check

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top biopharmadive.com News

Novartis to acquire Avidity Biosciences for about $12 billion — REUTERS / ixx511

Business · United States

Novartis to acquire Avidity Biosciences for about $12 billion

47% Center coverage: 55 sources

Swiss drugmaker Novartis on Sunday said it agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion in cash. Avidity stockholders will receive $72 per share in cash, representing a premium of 46% to the company's closing on Friday.See the Story

Lilly to Acquire Adverum Biotechnologies

Eli Lilly · United States

Lilly to Acquire Adverum Biotechnologies

75% Center coverage: 4 sources

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of intravitreal...See the Story

Merck Kidney Cancer Drug Succeeds in Two Large Trials

Medical · United States

Merck Kidney Cancer Drug Succeeds in Two Large Trials

100% Center coverage: 1 sources

The results could help expand use of Welireg, one of the medicines Merck is counting on to drive revenue growth when its top-selling immunotherapy Keytruda loses patent protection.See the Story

Breaking News Topics Related to biopharmadive.com